AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34506898 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellarex drug-coated balloon (DCB)
Number of subjects: 589
Study 34506898 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 589
Study 34506988 — intervention group
Group type: EXPERIMENTAL
Intervention: Total egg consumption (>1 egg/d)
Number of subjects: 8241
Study 34506988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried egg consumption (>1/2 egg/d)
Number of subjects: 8241
Study 34506988 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary intake and egg-sourced cholesterol intake
Number of subjects: 8241
Study 34507560 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with a stoma
Number of subjects: 376
Study 34507560 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking habits
Number of subjects: 376
Study 34507560 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 376
Study 34507560 — intervention group
Group type: EXPERIMENTAL
Intervention: American Society of Anesthesiologists physical status 3 and 4
Number of subjects: 376
Study 34507560 — intervention group
Group type: COMPARATOR
Intervention: No stoma treatment
Number of subjects: 376
Study 34507574 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl 12 mcg/h
Number of subjects: 60
Study 34507574 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release morphine 10 mg b.i.d.
Number of subjects: 60
Study 34507574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34507866 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative adjustments to communication challenges
Number of subjects: 62
Study 34507866 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative adjustments to comprehension challenges
Number of subjects: 62
Study 34507866 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative adjustments to visitation challenges
Number of subjects: 62
Study 34508027 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using biomarkers (C-reactive protein and white blood cells) for prediction of culture-proven EOS.
Number of subjects: 1685
Study 34508027 — intervention group
Group type: COMPARATOR
Intervention: Risk factors (RFs) alone for prediction of culture-proven EOS.
Number of subjects: 1685
Study 34508298 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI test with LiverMultiScan report
Number of subjects: 101
Study 34508298 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI test
Number of subjects: 101
Study 34508298 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive evaluation of the liver with MRI or ultrasound-based elastography
Number of subjects: 101
Study 34508298 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive methods and visual reports
Number of subjects: 101
Study 34508692 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 0/2h-algorithm using high-sensitivity cardiac troponin I (hs-cTnI) assay (ARCHITECT)
Number of subjects: 0
Study 34508692 — intervention group
Group type: COMPARATOR
Intervention: ESC 0/1h-algorithm
Number of subjects: 0
Study 34509298 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) used as tracer for pelvic lymphadenectomy and removal of upper paracervical lymphovascular tissue (UPLT)
Number of subjects: 145
Study 34509298 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of UPLT
Number of subjects: 145
Study 34509409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-worn accelerometers measuring Physical Average Daily Activity (PADA)
Number of subjects: 63
Study 34509409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-worn accelerometers measuring Total Average Daily Activity
Number of subjects: 63
Study 34509410 — intervention group
Group type: EXPERIMENTAL
Intervention: Management guided by pulmonary artery (PA) pressure monitoring
Number of subjects: 1200
Study 34509588 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoNaut 2D fusion imaging system
Number of subjects: 255
Study 34509588 — intervention group
Group type: COMPARATOR
Intervention: Control group (without EndoNaut 2D fusion imaging)
Number of subjects: 255
Study 34509774 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 89
Study 34509774 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia disorder (ID)
Number of subjects: 89
Study 34509774 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex performance measures
Number of subjects: 89
Study 34510123 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphisms (SNPs) in 76 different genes
Number of subjects: 92
Study 34510123 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of genes in adult mouse stria vascularis and organ of Corti
Number of subjects: 92
Study 34510123 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential genetic targets for SSNHL treatments
Number of subjects: 92
Study 34510198 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMOs) among secretors
Number of subjects: 107
Study 34510198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucosyllacto-N-hexaose among secretors
Number of subjects: 107
Study 34510198 — intervention group
Group type: EXPERIMENTAL
Intervention: Difucosyllacto-N-hexaose among secretors
Number of subjects: 107
Study 34510198 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-N-neotetraose (LNnT) among secretors
Number of subjects: 107
Study 34510198 — intervention group
Group type: EXPERIMENTAL
Intervention: Difucosyllactose among secretors
Number of subjects: 107
Study 34510198 — intervention group
Group type: EXPERIMENTAL
Intervention: Disialyllacto-N-hexaose and LNnT among non-secretors
Number of subjects: 107
Study 34510295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 556
Study 34510295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 556
Study 34510295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556
Study 34510295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID with MTX > 15 mg/week
Number of subjects: 556
Study 34510295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID with MTX ≤ 15 mg/week
Number of subjects: 556
Study 34510295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID with MTX > 15 mg/week
Number of subjects: 556
Study 34510361 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam prior to filgrastim
Number of subjects: 0
Study 34510361 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim only
Number of subjects: 0
Study 34510377 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) program consisting of supervised breathing, aerobic, strengthening, and stretching exercises for 8 weeks, 2 days a week
Number of subjects: 110
Study 34510377 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) program
Number of subjects: 110
Study 34510411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 5299
Study 34510411 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 5299
Study 34510485 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent antibiotic courses
Number of subjects: 0
Study 34510485 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite sensitization
Number of subjects: 0
Study 34510716 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation marker panel using five markers
Number of subjects: 239
Study 34510716 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation marker panel
Number of subjects: 239
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168)
Number of subjects: 235
Study 34511132 — intervention group
Group type: COMPARATOR
Intervention: First-line chemotherapy (n = 67)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with CD74-ROS1 fusions (n = 90)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with non-CD74 ROS1 fusions (n = 69)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with baseline brain metastasis (n = 45)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) without baseline brain metastasis (n = 123)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with intracranial-only progression (n = 40)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with extracranial-only progression (n = 64)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with concomitant TP53 mutations (n = 13)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with wild-type TP53 (n = 81)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with concomitant driver mutations (n = 9)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) without concomitant mutations (n = 58)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) with concomitant tumor suppressor genes (n = 25)
Number of subjects: 235
Study 34511132 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line crizotinib (n = 168) without concomitant tumor suppressor genes (n = 58)
Number of subjects: 235
Study 34511898 — intervention group
Group type: COMPARATOR
Intervention: HRR after 6MWT categorized as HRR≤5 bt/min
Number of subjects: 2127
Study 34511898 — intervention group
Group type: EXPERIMENTAL
Intervention: HRR after 6MWT categorized as HRR≥11 bt/min
Number of subjects: 2127
Study 34511898 — intervention group
Group type: EXPERIMENTAL
Intervention: HRR≤10 bt/min after 6MWT
Number of subjects: 2127
Study 34511974 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 210
Study 34511975 — intervention group
Group type: COMPARATOR
Intervention: PE/low-PTX3
Number of subjects: 236
Study 34511975 — intervention group
Group type: EXPERIMENTAL
Intervention: PE/high-PTX3
Number of subjects: 236
Study 34511975 — intervention group
Group type: EXPERIMENTAL
Intervention: PR/low-PTX3
Number of subjects: 236
Study 34511975 — intervention group
Group type: EXPERIMENTAL
Intervention: PR/high-PTX3
Number of subjects: 236
Study 34511975 — intervention group
Group type: EXPERIMENTAL
Intervention: High-PTX3
Number of subjects: 236
Study 34511975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of plasma PTX3 levels and PR
Number of subjects: 236
Study 34512014 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI)
Number of subjects: 747
Study 34512058 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 59
Study 34512058 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (deletion in exon 19 only)
Number of subjects: 59
Study 34512305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 100
Study 34513679 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-19 CAR-T immunotherapy (second generation CAR containing CD28 or 4-1BB therapy)
Number of subjects: 1
Study 34513681 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable rectal spacer balloon
Number of subjects: 24
Study 34513946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic-hyperoxic exposures
Number of subjects: 0
Study 34513946 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34513983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol
Number of subjects: 0
Study 34514286 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice Bran (RB) dietary supplementation for 6 months
Number of subjects: 47
Study 34514286 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RB supplementation)
Number of subjects: 47
Study 34514436 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccines (Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273)
Number of subjects: 96
Study 34514841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcation PCI
Number of subjects: 5498
Study 34514849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural stent thrombosis (IPST)
Number of subjects: 6006
Study 34514849 — intervention group
Group type: COMPARATOR
Intervention: No intraprocedural stent thrombosis (IPST)
Number of subjects: 6006
Study 34515101 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition (3D) catheter
Number of subjects: 100
Study 34515101 — intervention group
Group type: COMPARATOR
Intervention: High-resolution (2D) catheter
Number of subjects: 100
Study 34515148 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele carriers
Number of subjects: 70
Study 34515148 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake (macronutrients)
Number of subjects: 70
Study 34515148 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 70
Study 34515154 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 41
Study 34515215 — intervention group
Group type: EXPERIMENTAL
Intervention: HKT288 (0.3 mg/kg IV every 3 weeks)
Number of subjects: 9
Study 34515215 — intervention group
Group type: EXPERIMENTAL
Intervention: HKT288 (0.75 mg/kg cohort)
Number of subjects: 9
Study 34515215 — intervention group
Group type: EXPERIMENTAL
Intervention: HKT288 (0.3 mg/kg IV)
Number of subjects: 9
Study 34515303 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthful plant-based diet index (hPDI)
Number of subjects: 646
Study 34515303 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall plant-based diet index (PDI)
Number of subjects: 646
Study 34515303 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthful plant-based diet index (uPDI)
Number of subjects: 646
Study 34515338 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Number of subjects: 79
Study 34515544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonchemotherapy arm of Children's Oncology Group Study ARST1321
Number of subjects: 0
Study 34515905 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education years
Number of subjects: 321
Study 34515905 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased depression by CES-D score
Number of subjects: 321
Study 34515905 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tangible support
Number of subjects: 321
Study 34515905 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 321
Study 34515905 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education years (adjusted)
Number of subjects: 321
Study 34515905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangible social support (adjusted)
Number of subjects: 321
Study 34515993 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (mitomycin-C and 5-FU; gemcitabine; gemcitabine plus oxaliplatin; or capecitabine)
Number of subjects: 931
Study 34515993 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 931
Study 34515993 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant S-1 chemotherapy
Number of subjects: 931
Study 34515993 — intervention group
Group type: COMPARATOR
Intervention: No postoperative adjuvant chemotherapy (surgery alone)
Number of subjects: 931
Study 34516465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-Nurse Collaboration Scale
Number of subjects: 477
Study 34516465 — intervention group
Group type: EXPERIMENTAL
Intervention: Jefferson Scale of Attitudes Toward Physician-Nurse Collaboration
Number of subjects: 477
Study 34516656 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 890
Study 34516656 — intervention group
Group type: COMPARATOR
Intervention: Bilateral lateral rectus recession
Number of subjects: 890
Study 34516656 — intervention group
Group type: COMPARATOR
Intervention: Lateral rectus recession and medial rectus plication
Number of subjects: 890
Study 34516954 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel (target dose 5 × 10^5 CAR T cells)
Number of subjects: 115
Study 34516954 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 115
Study 34516956 — intervention group
Group type: EXPERIMENTAL
Intervention: AEx (aerobic exercise at 65-70% of age-predicted maximum heart rate for 45 min)
Number of subjects: 24
Study 34516956 — intervention group
Group type: EXPERIMENTAL
Intervention: REx (resistance exercise, 1-set to failure on 12 exercises)
Number of subjects: 24
Study 34516956 — intervention group
Group type: COMPARATOR
Intervention: CON (sedentary control)
Number of subjects: 24
Study 34517118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing (SDB)
Number of subjects: 77
Study 34517118 — intervention group
Group type: COMPARATOR
Intervention: No SDB (Control)
Number of subjects: 77
Study 34517841 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 32
Study 34518090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricemic group (SUA > 7 mg/dl in men, > 6 mg/dl in women)
Number of subjects: 6221
Study 34518090 — intervention group
Group type: EXPERIMENTAL
Intervention: SUA levels
Number of subjects: 6221
Study 34518090 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Roundness Index (BRI)
Number of subjects: 6221
Study 34518090 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Shape Index (BSI)
Number of subjects: 6221
Study 34518090 — intervention group
Group type: EXPERIMENTAL
Intervention: Various thresholds of elevated SUA levels
Number of subjects: 6221
Study 34518162 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy initiation during lockdown (16 March 2020 through 31 July 2020)
Number of subjects: 2229
Study 34518162 — intervention group
Group type: COMPARATOR
Intervention: No treatment (sham-control arm data from Minimally Classic/Occult Trial)
Number of subjects: 2229
Study 34518203 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 3804
Study 34518262 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education and exercise
Number of subjects: 1000
Study 34518262 — intervention group
Group type: COMPARATOR
Intervention: Reference cohort from the general population
Number of subjects: 1000
Study 34518555 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ASD
Number of subjects: 94
Study 34518555 — intervention group
Group type: COMPARATOR
Intervention: Children with typical development
Number of subjects: 94
Study 34518951 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy and azygoportal disconnection (LSD)
Number of subjects: 115
Study 34519109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 724
Study 34519109 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 724
Study 34519109 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 724
Study 34519109 — intervention group
Group type: EXPERIMENTAL
Intervention: High PPI dose (≥ 20 OE/day)
Number of subjects: 724
Study 34519109 — intervention group
Group type: COMPARATOR
Intervention: PPI use (general)
Number of subjects: 724
Study 34519109 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (≤20 OE/day)
Number of subjects: 724
Study 34519331 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure variability (BPV) measured as a continuous variable and by tertile of standard deviation (SD) of systolic BP.
Number of subjects: 6759
Study 34519356 — intervention group
Group type: COMPARATOR
Intervention: Continuous venovenous haemodiafiltration (CVVHDF)
Number of subjects: 1143
Study 34519356 — intervention group
Group type: COMPARATOR
Intervention: Pre-dilution haemofiltration
Number of subjects: 1143
Study 34519356 — intervention group
Group type: COMPARATOR
Intervention: Longer catheter (> 20 cm) targeting the right atrium
Number of subjects: 1143
Study 34519356 — intervention group
Group type: COMPARATOR
Intervention: Surface-modified double-lumen catheter
Number of subjects: 1143
Study 34519356 — intervention group
Group type: COMPARATOR
Intervention: Higher blood flow (≥ 250 mL/minute)
Number of subjects: 1143
Study 34519356 — intervention group
Group type: COMPARATOR
Intervention: More and shorter hollow fibre filters
Number of subjects: 1143
Study 34519356 — intervention group
Group type: COMPARATOR
Intervention: CVVHDF
Number of subjects: 1143
Study 34519356 — intervention group
Group type: COMPARATOR
Intervention: CVVHD
Number of subjects: 1143
Study 34519356 — intervention group
Group type: COMPARATOR
Intervention: Longer catheter
Number of subjects: 1143
Study 34519356 — intervention group
Group type: COMPARATOR
Intervention: Surface-modified double-lumen catheters
Number of subjects: 1143
Study 34519666 — intervention group
Group type: EXPERIMENTAL
Intervention: Video vignettes for the online intervention
Number of subjects: 109
Study 34519686 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia depth assessed by Narcotrend monitoring before stimulation
Number of subjects: 12
Study 34519686 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotrend index cutoff value of 41 or greater
Number of subjects: 12
Study 34519690 — intervention group
Group type: EXPERIMENTAL
Intervention: Search-and-treat strategy combined with biomarker screening (pepsinogens I and II, gastrin-17) for atrophic gastritis
Number of subjects: 3453
Study 34519690 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone invitations
Number of subjects: 3453
Study 34519690 — intervention group
Group type: COMPARATOR
Intervention: Mail invitations
Number of subjects: 3453
Study 34519823 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteogenesis Imperfecta (OI)
Number of subjects: 90
Study 34519823 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 90
Study 34519823 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-COL variants (OI)
Number of subjects: 90
Study 34519839 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD47 antibodies
Number of subjects: 0